Outlook Therapeutics Inc (NASDAQ:OTLK) has re-submitted its marketing application to the FDA, seeking approval for ONS-5010 for wet age-related macular degeneration…
Connect Biopharma Holdings Limited (NASDAQ:CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective,…
Home discount retailer Big Lots Inc (NYSE:BIG) reported a second-quarter FY22 sales decline of 7.6% year-on-year to $1.346 billion, marginally beating the…
The FDA has notified Curis Inc (NASDAQ: CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study of Emavusertib.
- SELECT trial of vopratelimab in combination with pimivalimab versus pimivalimab alone did not meet its primary endpoint of mean tumor change averaged over 9 and 18 weeks -
- Encouraging trends in improved mean tumor
Cybin Inc. (NEO:CYBN) (NYSE:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, is pleased to announce that the first